CP101
CP101-ASD-203
Phase 2 small_molecule terminated
Quick answer
CP101 for Autism Spectrum Disorder is a Phase 2 program (small_molecule) at Finch Therapeutics Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Finch Therapeutics Group
- Indication
- Autism Spectrum Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated